RIKEN suspends first clinical trial involving induced pluripotent stem cells

  title={RIKEN suspends first clinical trial involving induced pluripotent stem cells},
  author={K. Garber},
  journal={Nature Biotechnology},
  • K. Garber
  • Published 2015
  • Biology, Medicine
  • Nature Biotechnology
VOLUME 33 NUMBER 9 SEPTEMBER 2015 NATURE BIOTECHNOLOGY autologous transplants, which would have been much more informative. “There’s only been one patient with the autologous, which is a shame,” says Pete Coffey, a stem cell researcher at University College London. “An N of one is never good, that’s for sure.” For RIKEN’s future allogeneic trial, cells will come from CiRA, which is developing a bank of iPSCs from consenting individuals who have already donated to cord blood or peripheral blood… Expand

Paper Mentions

Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation
The translational potential of human induced pluripotent stem cells for clinical neurology
High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos
iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies
Creating human germ cells for unmet reproductive needs


Stem cells: The dark side of induced pluripotency